Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Reactive oxygen species (ROS)-driven oxidative stress has been recognized as a critical inducer of cancer cell death in response to therapeutic agents. Our previous studies have demonstrated that zinc finger protein (ZNF)32 is key to cell survival upon oxidant stimulation. However, the mechanisms by which
ZNF32
mediates cell death remain unclear. Here, we show that at moderate levels of ROS, Sp1 directly binds to two GC boxes within the
ZNF32
promoter to activate
ZNF32
transcription. Alternatively, at cytotoxic ROS concentrations,
ZNF32
expression is repressed due to decreased binding activity of Sp1.
ZNF32
overexpression maintains mitochondrial membrane potential and enhances the antioxidant capacity of cells to detoxify ROS, and these effects promote cell survival upon pro-oxidant agent treatment. Alternatively,
ZNF32
-deficient cells are more sensitive and vulnerable to oxidative stress-induced cell injury. Mechanistically, we demonstrate that complement 1q-binding protein (C1QBP) is a direct target gene of
ZNF32
that inactivates the p38
MAPK
pathway, thereby exerting the protective effects of
ZNF32
on oxidative stress-induced apoptosis. Taken together, our findings indicate a novel mechanism by which the Sp1-
ZNF32
-C1QBP axis protects against oxidative stress and implicate a promising strategy that
ZNF32
inhibition combined with pro-oxidant anticancer agents for hepatocellular carcinoma treatment.
...
PMID:ZNF32 protects against oxidative stress-induced apoptosis by modulating C1QBP transcription. 2649 55